The Manufacturers Life Insurance Company Has $2.46 Million Position in Chemed Corp. (CHE)

The Manufacturers Life Insurance Company trimmed its stake in shares of Chemed Corp. (NYSE:CHE) by 3.5% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 12,039 shares of the company’s stock after selling 441 shares during the period. The Manufacturers Life Insurance Company owned about 0.08% of Chemed Corp. worth $2,462,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Acrospire Investment Management LLC acquired a new stake in Chemed Corp. in the second quarter valued at approximately $120,000. Pacad Investment Ltd. lifted its position in shares of Chemed Corp. by 250.0% in the second quarter. Pacad Investment Ltd. now owns 700 shares of the company’s stock valued at $143,000 after acquiring an additional 500 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Chemed Corp. by 12.8% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 731 shares of the company’s stock valued at $150,000 after acquiring an additional 83 shares in the last quarter. Campbell & CO Investment Adviser LLC purchased a new position in shares of Chemed Corp. in the second quarter valued at approximately $209,000. Finally, World Asset Management Inc purchased a new position in shares of Chemed Corp. in the second quarter valued at approximately $216,000. 97.24% of the stock is currently owned by institutional investors.

A number of equities analysts recently commented on the company. Zacks Investment Research upgraded Chemed Corp. from a “hold” rating to a “buy” rating and set a $251.00 price objective on the stock in a research report on Thursday. TheStreet upgraded Chemed Corp. from a “c+” rating to an “a-” rating in a research report on Friday, October 27th. Royal Bank Of Canada lifted their price objective on Chemed Corp. to $232.00 and gave the company a “sector perform” rating in a research note on Tuesday, October 31st. KeyCorp reaffirmed a “hold” rating on shares of Chemed Corp. in a research note on Friday, October 27th. Finally, Oppenheimer Holdings, Inc. lifted their price objective on Chemed Corp. from $220.00 to $225.00 and gave the company an “outperform” rating in a research note on Friday, October 27th. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $236.00.

WARNING: This piece was reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another publication, it was stolen and republished in violation of US and international copyright law. The correct version of this piece can be read at https://www.com-unik.info/2017/11/05/the-manufacturers-life-insurance-company-has-2-46-million-position-in-chemed-corp-che.html.

Shares of Chemed Corp. (NYSE CHE) opened at $235.01 on Friday. The firm has a market capitalization of $3,752.17, a PE ratio of 28.94, a PEG ratio of 4.97 and a beta of 1.14. The company has a debt-to-equity ratio of 0.15, a current ratio of 0.50 and a quick ratio of 0.48.

Chemed Corp. (NYSE:CHE) last posted its earnings results on Thursday, October 26th. The company reported $2.15 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.00 by $0.15. Chemed Corp. had a return on equity of 27.69% and a net margin of 4.62%. The business had revenue of $417.40 million during the quarter, compared to the consensus estimate of $414.34 million. During the same period in the previous year, the business earned $1.73 EPS. The business’s quarterly revenue was up 6.3% on a year-over-year basis. analysts predict that Chemed Corp. will post 4.73 EPS for the current year.

The business also recently disclosed a dividend, which will be paid on Monday, December 4th. Shareholders of record on Monday, November 13th will be paid a dividend of $0.28 per share. The ex-dividend date of this dividend is Friday, November 10th. Chemed Corp.’s dividend payout ratio is presently 24.89%.

In related news, CEO Kevin J. Mcnamara sold 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 31st. The stock was sold at an average price of $223.42, for a total value of $2,234,200.00. Following the sale, the chief executive officer now owns 170,016 shares in the company, valued at approximately $37,984,974.72. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Spencer S. Lee sold 1,000 shares of the company’s stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $197.46, for a total value of $197,460.00. Following the completion of the sale, the insider now owns 37,809 shares in the company, valued at approximately $7,465,765.14. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 13,250 shares of company stock valued at $2,927,418. 4.90% of the stock is owned by company insiders.

About Chemed Corp.

Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.

Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Corp. (NYSE:CHE).

Institutional Ownership by Quarter for Chemed Corp. (NYSE:CHE)

What are top analysts saying about Chemed Corp.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Chemed Corp. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit